{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-064439","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.669479+00:00","generated_at":"2026-05-22T10:56:55.114063+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Standard BioTools Q1 2025 revenue $40.8M (-10% YoY); net loss $26.0M, adj EBITDA loss $16.9M","bullets":["First-quarter revenue $40.8M, down 10% YoY; consumables -16%, instruments +24%, services -16%.","Net loss $26.0M improved 19% YoY ($32.2M); adjusted EBITDA loss $16.9M improved 29%.","Non-GAAP gross margin 53.2%, down from 56.2% in Q1 2024 due to volume, mix, and pricing.","Cash & equivalents $260.7M, no material debt; FY2025 revenue outlook reaffirmed at $165-175M.","Operating expenses fell 38% YoY to $52.7M, driven by merger cost synergies and SBS productivity gains."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-064439","json":"https://secwatch.observer/filing/0000950170-25-064439.json","markdown":"https://secwatch.observer/filing/0000950170-25-064439.md","text":"https://secwatch.observer/filing/0000950170-25-064439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000095017025064439/0000950170-25-064439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000095017025064439/lab-20250506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T10:56:55.114063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}